Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia

被引:134
|
作者
Selleri, C
Sato, T
DelVecchio, L
Luciano, L
Barrett, AJ
Rotoli, B
Young, NS
Maciejewski, JP
机构
[1] UNIV NAPLES FEDERICO II, SCH MED, DIV HEMATOL, NAPLES, ITALY
[2] CARDARELLI HOSP, SERV IMMUNOHEMATOL, NAPLES, ITALY
[3] NHLBI, HEMATOL BRANCH, BETHESDA, MD 20892 USA
关键词
D O I
10.1182/blood.V89.3.957
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Interferon-alpha (IFN-alpha) is an established treatment for chronic myelogenous leukemia (CML) in chronic phase, but the mechanism of its antileukemic activity is not clear. One possible mechanism of action might include the induction of apoptosis, and especially Fas-mediated cell killing may play an important role in the elimination of malignant cells. We investigated Fas receptor (Fas-R) expression and the consequences of Fas-R triggering in CML patients. Using two-color flow cytometry, we found a significantly higher number of Fas-R-expressing CD34(+) cells in the bone marrow (BM) of CML patients compared with normal subjects. We have previously shown that IFN-gamma induces Fas-R expression on CD34(+) cells; in this study, we investigated whether IFN-alpha induces Fas-R expression on CML progenitor cells. Dose-dependent induction of Fas-R expression was observed after IFN-alpha stimulation of CD34(+) cells from CML BM. In methylcellulose culture, IFN-alpha alone at a therapeutic concentration showed only marginal antiproliferative effects on both normal and CML BM progenitors. In contrast, a Fas-R agonist, the anti-CD95 monoclonal antibody CH11. inhibited colony formation from normal progenitors, and the inhibition was even stronger on CML progenitors. When CML BM cells were cultured in the presence of IFN-alpha, Fas-R-mediated inhibition of colony growth was potentiated in a dose-dependent fashion, consistent with IFN-alpha induction of Fas-R expression. This functional effect did not require the presence of accessory cells, since similar results were obtained with purified CD34(+) cells. In suspension cultures, we demonstrated that suppression of CML hematopoiesis by IFN-alpha and Fas-R agonist was exerted through Fas-R-mediated induction of apoptosis. Our findings suggest that the Fas-R/Fas-ligand system might be involved in the immunologic regulation of CML progenitor growth and that its effect can be amplified by IFN-alpha. (C) 1997 by The American Society of Hematology.
引用
收藏
页码:957 / 964
页数:8
相关论文
共 50 条
  • [41] RECOMBINANT HUMAN INTERFERON-ALPHA INDUCED CYTOREDUCTION IN CHRONIC MYELOGENOUS LEUKEMIA - RESULTS OF A MULTICENTER STUDY
    WERTER, M
    DEWITTE, R
    JANSSEN, J
    DEPAUW, B
    HAANEN, C
    BLUT, 1988, 56 (05): : 209 - 212
  • [42] Results of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older
    Cortes, J
    Kantarjian, H
    OBrien, S
    Robertson, LE
    Pierce, S
    Talpaz, M
    AMERICAN JOURNAL OF MEDICINE, 1996, 100 (04): : 452 - 455
  • [43] Fas mediated modulation of BCR/ABL in chronic myelogenous leukemia results in differential effects on apoptosis and correlates with clinical response to IFN-alpha.
    Selleri, C
    Maciejewski, JP
    Pane, F
    Luciano, L
    Raiola, A
    Risitano, AM
    Mostarda, I
    Salvatore, F
    Rotoli, B
    BLOOD, 1997, 90 (10) : 357 - 357
  • [44] MOLECULAR MONITORING OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA ON INTERFERON-ALPHA THERAPY BY QUANTITATIVE SOUTHERN BLOT
    REITER, A
    SKLADNY, H
    HOCHHAUS, A
    HEHLMANN, R
    EXPERIMENTAL HEMATOLOGY, 1995, 23 (08) : 792 - 792
  • [45] PREDICTING COMPLETE CYTOGENETIC RESPONSE IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS TREATED WITH RECOMBINANT INTERFERON-ALPHA
    MAHON, FX
    MONTASTRUC, M
    FABERES, C
    REIFFERS, J
    BLOOD, 1994, 84 (10) : 3592 - 3594
  • [46] Acquired factor VIII inhibitor as presentation of chronic myelogenous leukemia during interferon-alpha therapy
    Zheng, Wen-li
    Zhang, Guang-sen
    Shen, Jian-kai
    Pei, Min-fei
    Peng, Hong-ling
    Xu, Min
    THROMBOSIS RESEARCH, 2011, 128 (02) : 202 - 203
  • [47] Emergence of unusual cytogenetic abnormalities under interferon-alpha therapy in patients with chronic myelogenous leukemia
    Maloisel, F
    Uettwiller, F
    Laplace, A
    Lioure, B
    Herbrecht, R
    Mark, M
    Dufour, P
    CANCER GENETICS AND CYTOGENETICS, 1999, 113 (02) : 172 - 176
  • [48] MOLECULAR ELIMINATION OF PH(1) CLONE IN A CHRONIC MYELOGENOUS LEUKEMIA PATIENT WITH INTERFERON-ALPHA ALONE
    ISHIYAMA, K
    SATOH, S
    IGARASHI, Y
    KUMAGAI, H
    YAHAGI, A
    SASAKI, H
    LEUKEMIA, 1994, 8 (12) : 2243 - 2245
  • [49] EFFECT OF INTERFERON-ALPHA IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN THE ACCELERATED PHASE - CYTOGENETIC AND MOLECULAR STUDIES
    OGURA, H
    TANI, K
    KOZAI, Y
    WATARI, K
    KODO, H
    OZAWA, K
    ASANO, S
    TAKAKU, F
    JAPANESE JOURNAL OF CANCER RESEARCH, 1990, 81 (6-7): : 682 - 686
  • [50] A Guide to the Use of Interferon-Alpha in the Management of Chronic Myelogenous Leukaemia
    Jorge Cortes
    Susan O’Brien
    BioDrugs, 2000, 14 : 211 - 220